Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

 16.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 30.60
  • 52 Week Low: 12.60
  • Currency: UK Pounds
  • Shares Issued: 687.01m
  • Volume: 0
  • Market Cap: £109.92m
  • Beta: 0.05

Open Orphan subsidiary secures contract renewal with 'major' pharmaceutical client

By Iain Gilbert

Date: Monday 15 Nov 2021

LONDON (ShareCast) - (Sharecast News) - Contract research organisation Open Orphan said on Monday that its Venn Life Sciences subsidiary had signed a contract renewal with an unnamed "major global pharmaceutical client" worth £1.5m over a two-year period.
Open Orphan stated the renewed contract would commence in January 2022, with the Venn team set to provide dedicated clinical pharmacokinetics support to the client on |an array of drug development programmes".

Chairman Cathal Friel said: "We are delighted to see this contract renewal signed by the Venn team in Breda with a client that it has been working with since 2012.

"The continued support by Venn to a distinguished partner such as this demonstrates the value of Venn's clinical pharmacokinetics offering, as part of its comprehensive offering in drug development consultancy, clinical trial design and execution."

As of 1130 GMT, Open Orphan shares were up 1.25% at 20.25p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 16.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 30.60
52 Week Low 12.60
Volume 0
Shares Issued 687.01m
Market Cap £109.92m
Beta 0.05

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
74.06% below the market average74.06% below the market average74.06% below the market average74.06% below the market average74.06% below the market average
27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average
Price Trend
55.83% below the market average55.83% below the market average55.83% below the market average55.83% below the market average55.83% below the market average
45.95% below the sector average45.95% below the sector average45.95% below the sector average45.95% below the sector average45.95% below the sector average
Income
80.03% below the market average80.03% below the market average80.03% below the market average80.03% below the market average80.03% below the market average
50% below the sector average50% below the sector average50% below the sector average50% below the sector average50% below the sector average
Growth
64.53% above the market average64.53% above the market average64.53% above the market average64.53% above the market average64.53% above the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average

What The Brokers Say

Strong Buy 3
Buy 4
Neutral 0
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

  Latest Previous
  Final Final
Ex-Div 15-May-25 18-Apr-24
Paid 11-Jun-25 20-May-24
Amount 0.20p 0.20p

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Hvivo Key Personnel

CEO Yamin Mo' Khan

Top of Page